Glaukos Corporation (GKOS) News

Glaukos Corporation (GKOS): $38.94

-1.51 (-3.73%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Filter GKOS News Items

GKOS News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

GKOS News Highlights

  • For GKOS, its 30 day story count is now at 9.
  • Over the past 23 days, the trend for GKOS's stories per day has been choppy and unclear. It has oscillated between 1 and 2.
  • The most mentioned tickers in articles about GKOS are DNA, APDN and AVXL.

Latest GKOS News From Around the Web

Below are the latest news stories about GLAUKOS Corp that investors may wish to consider to help them evaluate GKOS as an investment opportunity.

Glaukos Corporation (NYSE:GKOS) Just Reported Annual Earnings: Have Analysts Changed Their Mind On The Stock?

Glaukos Corporation ( NYSE:GKOS ) shareholders are probably feeling a little disappointed, since its shares fell 2.5...

Yahoo | February 24, 2022

Glaukos Corporation (GKOS) CEO Tom Burns on Q4 2021 Results - Earnings Call Transcript

Glaukos Corporation (GKOS) Q4 2021 Earnings Conference Call February 22, 2022 16:30 ET Company Participants Chris Lewis - Vice President of Investor Relations & Corporate Affairs Tom Burns - President & Chief Executive Officer Joe Gilliam - Chief Financial Officer Alex Thurman - Vice President of Finance Chris Calcaterra -...

SA Transcripts on Seeking Alpha | February 23, 2022

Glaukos (GKOS) Q4 Earnings and Revenues Surpass Estimates

Despite reporting a fourth-quarter loss, Glaukos' (GKOS) results reflect a noticeable rise in revenues.

Yahoo | February 23, 2022

Glaukos (GKOS) Reports Q4 Loss, Tops Revenue Estimates

Glaukos (GKOS) delivered earnings and revenue surprises of 16.22% and 8.86%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Yahoo | February 22, 2022

Glaukos Corporation Announces Fourth Quarter and Full Year 2021 Financial Results

SAN CLEMENTE, Calif., February 22, 2022--Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced financial results for the fourth quarter and full year ended December 31, 2021. Key highlights include:

Yahoo | February 22, 2022

Earnings Preview: Glaukos (GKOS) Q4 Earnings Expected to Decline

Glaukos (GKOS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Yahoo | February 15, 2022

Analysts Offer Insights on Healthcare Companies: Applied DNA Sciences (APDN), Glaukos (GKOS) and Anavex Life Sciences (AVXL)

There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Applied DNA Sciences (APDN – Research Report), Glaukos (GKOS – Research Report) and Anavex Life Sciences (AVXL – Research Report) with bullish sentiments. Applied DNA Sciences (APDN) In a report released today, Yi Chen from H.C. Wainwright reiterated a Buy rating on Applied DNA Sciences, with a price target of $6.00. The company's shares closed last Thursday at $3.11, equals to its 52-week low of $3.11. According to TipRanks.

Howard Kim on TipRanks | February 11, 2022

Glaukos Announces Executive Leadership Changes

SAN CLEMENTE, Calif., February 07, 2022--Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced several executive leadership changes to support the company’s future growth and strategic plans. The following executive changes will become effective on April 1, 2022:

Yahoo | February 7, 2022

Glaukos Corporation to Release Fourth Quarter and Full Year 2021 Financial Results after Market Close on February 22

SAN CLEMENTE, Calif., February 01, 2022--Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, plans to release fourth quarter and full year 2021 financial results after the market close on Tuesday, February 22, 2022. The company’s management will discuss the results during a conference call and simultaneous webcast at 1:30 p.m. PST (4:30 p.m. EST) on February

Yahoo | February 1, 2022

Analysts Are Bullish on Top Healthcare Stocks: SAGE Therapeutics (SAGE), Glaukos (GKOS)

There's a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on SAGE Therapeutics (SAGE – Research Report) and Glaukos (GKOS – Research Report) with bullish sentiments. SAGE Therapeutics (SAGE) Needham analyst Ami Fadia maintained a Buy rating on SAGE Therapeutics today and set a price target of $85.00. The company's shares closed last Friday at $42.93, close to its 52-week low of $36.13. According to TipRanks.

Brian Anderson on TipRanks | January 18, 2022


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!




Page generated in 0.5849 seconds.